Navigation Links
New Therapy for Enlarged Prostate May Bypass Unpleasant Side Effects
Date:3/29/2011

By Amanda Gardner
HealthDay Reporter

TUESDAY, March 29 (HealthDay News) -- A minimally invasive treatment for enlarged prostate that limits blood supply to the prostate seems to be just as effective as surgery but without the risk of debilitating side effects, such as impotence and urinary incontinence.

The treatment -- called prostatic artery embolization, or PAE -- is ready to be used in certain patients, namely those with a prostate larger than 60 cubic centimeters, "with severe lower urinary tract symptoms and a weakened urinary stream," said Dr. Joao Martins Pisco, lead author of a study slated to be presented March 29 at the annual meeting of the Society of Interventional Radiology in Chicago.

But other experts aren't so sure.

Drugs are used to treat most patients with an enlarged prostate, with only about 10 percent qualifying for surgery to remove the entire gland, said Dr. Elizabeth Kavaler, a urologist at Lenox Hill Hospital in New York City.

"Because medication is so effective, most of the patients that we treat surgically are in pretty bad shape," she added. And while this study showed some symptomatic improvement, it didn't have enough objective data to show that the new technique would surpass surgery, she said.

Benign prostate hyperplasia, also known as enlarged prostate, is a non-cancerous condition familiar to millions of aging males. The condition occurs when the prostate gland slowly enlarges and presses on the urethra, constricting the flow of urine.

Enlarged prostate is characterized by a host of unpleasant symptoms, including weak or slow urine flow, an urgent need to urinate frequently, incomplete bladder emptying and having to get up repeatedly at night to urinate.

The surgery for enlarged prostate -- transurethral resection of the prostate, or TURP -- is used for men whose prostates are smaller than 60 to 80 cubic centimeters. The procedure is performed under general anesthesia and involves a hospital stay.

Meanwhile, there is no size limitation for PAE, which requires only local anesthesia and also lowers the risk of other side effects, such as blood loss and retrograde ejaculation, which occurs when semen leaks into the bladder, researchers said. PAE can be an outpatient procedure as well.

For the procedure, a catheter is inserted into the femoral artery in the groin. The catheter delivers tiny "grains" to the arteries that lead to the prostate, which block blood flow and lead to shriveling of the gland.

In this study, PAE helped most of the 67 patients who underwent the procedure, according to the researchers, who noted that 66 men who had not responded to medications experienced improvements in symptoms as well as a reduction in prostate volume. After nine months, none had experienced sexual dysfunction and 25 percent still reported improvements.

However, the authors did not see as great an improvement in "urodynamic" results, such as improved flow rate of the urine, which would indicate how well the bladder and urethra are performing; in this area, the patients did not improve as much as those who underwent TURP surgery, they noted.

Another drawback is that few doctors are trained in PAE so far, said Pisco, chair of radiology at Hospital Pulido Valente and professor in the Faculty of Medical Sciences at New University of Lisbon in Portugal.

Other minimally invasive treatments for enlarged prostate that are currently available are less effective and have a greater risk of a need for reoperation, according to background materials that accompanied the study.

Dr. Franklin Lowe, associate director of urology at St. Luke's-Roosevelt Hospital in New York City, said PAE was "unlikely" to be used much to treat enlarged prostate.

Current surgical procedures typically require no more than one night in the hospital and complications such as incontinence and impotence are uncommon, he said.

"PAE is potentially fraught with complications," Lowe said, adding that the study follow-up of less than one year was short for a disease that lasts decades.

Since the study is being presented at a medical meeting and has not yet been published in a peer-reviewed journal, the findings should be considered preliminary.

More information

The U.S. National Institutes of Health has more on enlarged prostate.

SOURCES: Joao Martins Pisco, M.D., professor and chair of radiology, Hospital Pulido Valente and professor, Faculty of Medical Sciences, New University of Lisbon, Portugal; Elizabeth Kavaler, M.D., urologist, Lenox Hill Hospital, New York City; Franklin Lowe, M.D., associate director, urology, St. Luke's-Roosevelt Hospital in New York City; Society of Interventional Radiology, study abstract and news release, March 29, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. For potentially crippling dystonia, earlier deep brain therapy gets better, quicker results
2. Scientists devise targeted therapy strategy for rare form of childhood cancer
3. FDA approves ipilimumab, an immunotherapy, to treat metastatic melanoma
4. Novel immunotherapy drug receives FDA approval for the treatment of metastatic melanoma
5. Interest in Toys May Predict Success of Autism Home Therapy
6. Short Course of Hormone Therapy Boosts Prostate Cancer Survival: Study
7. Penn researchers uncover novel immune therapy for pancreatic cancer
8. LSUHSC research finds protein that protects cancer cells from chemo and radiation therapy
9. Stem Cell Therapy Shrinks Enlarged Hearts
10. Self-administered light therapy may improve cognitive function after traumatic brain injury
11. Gene Therapy May Help Reverse Parkinsons Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Therapy for Enlarged Prostate May Bypass Unpleasant Side Effects
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s ... together more than 200 of the country’s top healthcare executives to share insights ... true benefit of the Forum is the provider-centric perspective, experience, expertise and strategy ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience signed a ... network of laboratory service centers across the country. Launched in April of 2015, Apifiny ... detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care ...
(Date:2/10/2016)... ... February 10, 2016 , ... A ... Ohio Safety Congress and Expo event March 9-11, 2016. Hosted by Ohio's Bureau ... Center. , As the longest running and largest worker's compensation event in ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... 1 UNF Drive, Jacksonville, FL 32224, February 26th: Amateur & Professional Divisions ... Division - Time: 7:00pm – 10:00pm | Ticket Prices $30, Social Media: ...
(Date:2/10/2016)... ... February 10, 2016 , ... Anxiety of older Americans ... start of Medicare Part D a decade ago, according to The Senior Citizens ... adults on how they are coping with rapidly rising costs. “The implications are ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
(Date:2/10/2016)...  Rich Pharmaceuticals, Inc. (OTC Markets: RCHA) ("Rich Pharmaceuticals" ... of its issued and outstanding shares of common stock ... 11, 2016. The Company,s common stock will trade on ... temporary ticker symbol "RCHAD". After 20 trading days, the ... (RCHA).  --> --> ...
(Date:2/10/2016)... , Feb. 10, 2016  The Baylor ... received an in-kind gift from ... VeinViewer® Vision vein finder for the nursing ... students as they learn how to start ... with traditional technique. ...
Breaking Medicine Technology: